Treatment of high-risk Philadelphia chromosome-negative acute lymphoblastic leukemia in adolescents and adults according to early cytologic response and minimal residual disease after consolidation assessed by flow cytometry: Final results of the PETHEMA ALL-AR-03 trial

Journal of Clinical Oncology

Volumn 32, Issue 15, 2014, Pages 1595-1604

  Ribera, Josep Maria ^a   Oriol, Albert ^a   Morgades, Mireia ^a   Montesinos, Pau ^e   Sarrà, Josep ^g   González Campos, José ^h   Brunet, Salut ^b   Tormo, Mar ^f   Fernández Abellán, Pascual ⁱ   Guàrdia, Ramon ^j   Bernal, María Teresa ^k   Esteve, Jordi ^c   Barba, Pere ^d   Moreno, María José ^l   Bermúdez, Arancha ^m   Cladera, Antonia ⁿ   Escoda, Lourdes ^o   García Boyero, Raimundo ^p   Del Potro, Eloy ^q   Bergua, Juan ^s   Amigo, María Luz ^t   Grande, Carlos ^r   Rabuñal, María José ^u   Hernández Rivas, Jesús María ^v   Feliu, Evarist ^a   more..

^a HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^b HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^c HOSPITAL CLÍNIC   (Spain)

^d HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^e HOSPITAL UNIVERSITARIO LA FE   (Spain)

^f HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^g HOSPITAL DURAN I REYNALS   (Spain)

^h HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

ⁱ HOSPITAL GENERAL UNIVERSITARIO DE ALICANTE   (Spain)

^j CATALAN INSTITUTE OF ONCOLOGY   (Spain)

^k HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

^l HOSPITAL UNIVERSITARIO VIRGEN DE LA VICTORIA   (Spain)

^m HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

ⁿ HOSPITAL SON LLÀTZER   (Spain)

^o HOSPITAL UNIVERSITARI JOAN XXIII   (Spain)

^p HOSPITAL GENERAL DE CASTELLÓN   (Spain)

^q HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^r HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^s HOSPITAL SAN PEDRO DE ALCÁNTARA   (Spain)

^t HOSPITAL MORALES MESEGUER   (Spain)

^u HOSPITAL XERAL CALDE   (Spain)

^v HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ASPARAGINASE; CYCLOPHOSPHAMIDE; CYTARABINE; DAUNORUBICIN; DEXAMETHASONE; HYDROCORTISONE; MERCAPTOPURINE; METHOTREXATE; MITOXANTRONE; PREDNISONE; TENIPOSIDE; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ACUTE MONOCYTIC LEUKEMIA; ADOLESCENT; ADOLESCENT DISEASE; ADULT; ADULT DISEASE; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PROGNOSIS; CANCER RISK; CANCER SURVIVAL; CANCER THERAPY; CONSOLIDATION CHEMOTHERAPY; CONTROLLED STUDY; CYTOLOGY; DISEASE FREE SURVIVAL; FEMALE; FLOW CYTOMETRY; HUMAN; INDUCTION CHEMOTHERAPY; LYMPHOBLASTOMA; MAINTENANCE CHEMOTHERAPY; MAJOR CLINICAL STUDY; MALE; MINIMAL RESIDUAL DISEASE; OVERALL SURVIVAL; PHILADELPHIA CHROMOSOME NEGATIVE ACUTE LYMPHOBLASTIC LEUKEMIA; PHILADELPHIA CHROMOSOME NEGATIVE CELL; PRIORITY JOURNAL; AGE; CLINICAL TRIAL; GENETIC PREDISPOSITION; GENETICS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; MULTIVARIATE ANALYSIS; PATHOLOGY; PATIENT SELECTION; PHENOTYPE; PHILADELPHIA 1 CHROMOSOME; PREDICTIVE VALUE; PROPORTIONAL HAZARDS MODEL; RISK FACTOR; SPAIN; STATISTICAL MODEL; TIME; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; AGE FACTORS; CONSOLIDATION CHEMOTHERAPY; DISEASE-FREE SURVIVAL; FEMALE; FLOW CYTOMETRY; GENETIC PREDISPOSITION TO DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; KAPLAN-MEIER ESTIMATE; LOGISTIC MODELS; MAINTENANCE CHEMOTHERAPY; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM, RESIDUAL; PATIENT SELECTION; PHENOTYPE; PHILADELPHIA CHROMOSOME; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; RISK FACTORS; SPAIN; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84903546885     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2013.52.2425     Document Type: Article

References (33)

1. Bassan R, Hoelzer D: Modern therapy of acute lymphoblastic leukemia. J Clin Oncol 29:532-543, 2011
2. Fielding AK: Current therapeutic strategies in adult acute lymphoblastic leukemia. Hematol Oncol Clin North Am 25:1255-1279, 2011
3. Rowe JM: Optimal management of adults with ALL. Br J Haematol 144:468-483, 2009
4. Gökbuget N, Hoelzer D: Treatment of adult acute lymphoblastic leukemia. Semin Hematol 46:64-75, 2009
5. Brüggemann M, Gökbuget N, Kneba M: Acute lymphoblastic leukemia: Monitoring minimal residual disease as a therapeutic principle. Semin Oncol 39:47-57, 2012
6. Brüggemann M, Raff T, Kneba M: Has MRD monitoring superseded other prognostic factors in adult ALL? Blood 120:4470-4481, 2012
7. Brüggemann M, Raff T, Flohr T, et al: Clinical significance of minimal residual disease quantification in adult patients with standard-risk acute lymphoblastic leukemia. Blood 107:1116-1123, 2006 (Pubitemid 43156313)
8. Gökbuget N, Kneba M, Raff T, et al: Adult patients with acute lymphoblastic leukemia and molecular failure display a poor prognosis and are candidates for stem cell transplantation and targeted therapies. Blood 120:1868-1876, 2012
9. Bassan R, Spinelli O, Oldani E, et al: Improved risk classification for risk-specific therapy based on the molecular study of minimal residual disease (MRD) in adult acute lymphoblastic leukemia (ALL). Blood 113:4153-4162, 2009
10. Raff T, Gökbuget N, Lüschen S, et al: Molecular relapse in adult standard-risk ALL patients detected by prospective MRD monitoring during and after maintenance treatment: Data from the GMALL 06/99 and 07/03 trials. Blood 109:910-915, 2007 (Pubitemid 46220634)
11. Sellar R, Goldstone AH, Lazarus HM: Redefining transplant in acute leukemia. Curr Treat Options Oncol 12:312-328, 2011
12. Ribera JM: Allogeneic stem cell transplantation for adult acute lymphoblastic leukemia: When and how. Haematologica 96:1083-1086, 2011
13. Mitelman F, ed. ISCN: An International System for Human Cytogenetic Nomenclature. Basel, Switzerland, Karger, 1995
14. Dworzak MN, Gaipa G, Ratei R, et al: Standardization of flow cytometric minimal residual disease evaluation in acute lymphoblastic leukemia: Multicentric assessment is feasible. Cytometry B Clin Cytom 74:331-340, 2008
15. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
16. Peto R, Pike MC: Conservatism of the approximation (O-E)2-E in the logrank test for survival data or tumor incidence data. Biometrics 29:579-584, 1973
17. Cox DR: Regression models and life tables. J R Stat Soc B 34:187-220, 1972
18. Goldstone AH, Richards SM, Lazarus HM, et al: In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolidation/maintenance chemotherapy in all patients: Final results of the International ALL Trial (MRC UKALL XII/ECOG E2993). Blood 111:1827-1833,
19. Ribera JM, Oriol A, Bethencourt C, et al: Comparison of intensive chemotherapy, allogeneic or autologous stem cell transplantation as post-remission treatment for adult patients with high-risk acute lymphoblastic leukemia. Results of the PETHEMA ALL-93 trial. Haematologica 90:1346-1356, 2005 (Pubitemid 41503650)
20. Gupta V, Richards S, Rowe J, et al: Allogeneic, but not autologous, hematopoietic cell transplantation improves survival only among younger adults with acute lymphoblastic leukemia in first remission: An individual patient data meta-analysis. Blood 121:339-350, 2013
21. Patel B, Rai L, Buck G, et al: Minimal residual disease is a significant predictor of treatment failure in non T-lineage adult acute lymphoblastic leukaemia: Final results of the international trial UKALL XII/ECOG2993. Br J Haematol 148:80-89, 2010
22. Holowiecki J, Krawczyk-Kulis M, Giebel S, et al: Status of minimal residual disease after induction predicts outcome in both standard and high-risk Ph-negative adult acute lymphoblastic leukaemia: The Polish Adult Leukemia Group ALL 4-2002 MRD Study. Br J Haematol 142:227-237, 2008 (Pubitemid 351994055)
23. Vora A, Goulden N, Wade R, et al: Treatment reduction for children and young adults with low-risk acute lymphoblastic leukaemia defined by minimal residual disease (UKALL 2003): A randomised controlled trial. Lancet Oncol 14:199-209, 2013
24. Conter V, Bartram CR, Valsecchi MG, et al: Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: Results in 3184 patients of the AIEOP-BFM ALL 2000 study. Blood 115:3206-3214, 2010
25. Topp MS, Kufer P, Gökbuget N, et al: Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival. J Clin Oncol 29:2493-2498, 2011
26. Topp MS, Gökbuget N, Zugmaier G, et al: Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL. Blood 120:5185-5187, 2012
27. Vidriales MB, Pérez JJ, López-Berges MC, et al: Minimal residual disease in adolescent (older than 14 years) and adult acute lymphoblastic leukemias: Early immunophenotypic evaluation has high clinical value. Blood 101:4695-4700, 2003 (Pubitemid 36857722)
28. Dworzak MN, Gaipa G, Schumich A, et al: Modulation of antigen expression in B-cell precursor acute lymphoblastic leukemia during induction therapy is partly transient: Evidence for a drug-induced regulatory phenomenon-Results of the AIEOP-BFM-ALL-FLOW-MRD-Study Group. Cytometry B Clin Cytom 78:147-153, 2010
29. Brüggemann M, Schrauder A, Raff T, et al: Standardized MRD quantification in European ALL trials: Proceedings of the Second International Symposium on MRD assessment in Kiel, Germany, 18-20 September 2008. Leukemia 24:521-535, 2010
30. van Dongen JJ, Lhermitte L, Böttcher S, et al: EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes. Leukemia 26:1908-1975, 2012
31. Denys B, van der Sluijs-Gelling AJ, Homburg C, et al: Improved flow cytometric detection of minimal residual disease in childhood acute lymphoblastic leukemia. Leukemia 27:635-641, 2013
32. Garand R, Beldjord K, Cavé H, et al: Flow cytometry and IG/TCR quantitative PCR for minimal residual disease quantitation in acute lymphoblastic leukemia: A French multicenter prospective study on behalf of the FRALLE, EORTC and GRAALL. Leukemia 27:370-376, 2013
33. Kantarjian H, Thomas D, Wayne AS, et al: Monoclonal antibody-based therapies: A new dawn in the treatment of acute lymphoblastic leukemia. J Clin Oncol 30:3876-3883, 2012